Drug-labels.com

Mylan-Tolterodine ER: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Post Market
Strength:
2 mg, 4 mg
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Mylan-Tolterodine ER

What the medication is used for:

The name of this medication is MYLAN-TOLTERODINE ER. It is used for the treatment of the symptoms of overactive bladder which include frequency, urgency, and urge incontinence.

REMEMBER: This medication is for YOU. Never give it to others. It may harm them even if their symptoms are the same as yours.

What it does:

Tolterodine works to prevent bladder contractions or spasms. This results in more bladder capacity and less frequency, urgency and involuntary loss of urine.

When it should not be used:

You should not take MYLAN-TOLTERODINE ER if you have:

  • urinary retention,
  • gastric retention,
  • uncontrolled narrow angle glaucoma,
  • known hypersensitivity to tolterodine L-tartrate or any of the other ingredients in MYLAN-TOLTERODINE ER.

What the medicinal ingredient is:

Each capsule contains film-coated beads of 2 mg or 4 mg of the active ingredient, tolterodine L-tartrate. The film-coated beads dissolve over time, releasing the active ingredient over 24 hours.

What the important nonmedicinal ingredients are:

The capsules also contain the following inactive ingredients: Ethylcellulose, FD&C Blue #2, gelatin, hypromellose, iron oxide yellow (2 mg capsules only), starch, sucrose, talc, titanium dioxide; Ink: povidone, propylene glycol, shellac and sodium hydroxide.

What dosage forms it comes in:

MYLAN-TOLTERODINE ER 2 mg is a blue-green capsule printed with “MYLAN” over “TT 2” in white ink on both the cap and body.

MYLAN-TOLTERODINE ER 4 mg is a blue capsule printed with “MYLAN” over “TT 4” in white ink on both the cap and body.

MYLAN-TOLTERODINE ER may have an effect on the electrical activity of the heart. This effect can be measured as a change in the electrocardiogram (ECG). It is important to follow the instructions of your doctor with regard to dosing or any special tests. In very rare cases, drugs with an effect on the ECG can lead to disturbances in heart rhythm (arrhythmias/dysrhythmias). These heart rhythm disturbances are more likely in patients with risk factors, such as heart disease, or in the presence of certain interacting drugs. If you experience any symptoms of a possible heart rhythm disturbance, such as dizziness, palpitations (sensation of rapid pounding, or irregular heart beat), fainting, or seizures, you should stop taking MYLAN-TOLTERODINE ER and seek immediate medical attention.

BEFORE you use MYLAN-TOLTERODINE ER talk to your doctor or pharmacist if:

  • you are pregnant, or trying to become pregnant

  • you are breastfeeding your child
  • you have myasthenia gravis (a chronic autoimmune neuromuscular disease which cause muscle weakness)
  • you have stomach problems affecting passage and digestion of food
  • you have liver problems
  • you have kidney problems
  • you are taking medication bought without a prescription. They may affect your condition, or how MYLAN-TOLTERODINE ER works for you.
  • you are a female or are over 65 years in age; you have a disorder known as Long QT Syndrome; a heart disease; a history of stroke or brain hemorrhage; a personal history of fainting spells; a family history of sudden cardiac death at <50 years; electrolyte disturbances (e.g., low blood potassium levels); an eating disorder or are following an extreme diet; diabetes, especially with associated nerve disorders

INTERACTIONS WITH THIS MEDICATION

The following list includes some, but not all, of the drugs that may increase the risk of side effects while receiving MYLAN-TOLTERODINE ER. You should check with your doctor or pharmacist before taking any other medication with MYLAN-TOLTERODINE ER.

Drugs that may interact with MYLAN-TOLTERODINE ER include:

  • other drugs that possess antimuscarinic/anticholinergic properties (drugs that cause blurred vision, constipation, dry

ABOUT THIS MEDICATION

WARNINGS AND PRECAUTIONS

INTERACTIONS WITH THIS MEDICATION

IMPORTANT: PLEASE READ

  • mouth, etc.)
  • antifungals (drugs to treat fungal infections, such as,

    fluconazole, ketoconazole, or itraconazole)

  • antibiotics (ie. erythromycin, clarithromycin)
  • cyclosporine (a drug to prevent rejection of organ transplants)
  • vinblastine (a drug to treat some types of cancer)
  • antiarrhythmics (drugs that stabilize the heart rhythm function, such as procainamide, quinidine, amiodarone, sotalol, etc.)
  • antidepressants (mood disorder drugs)
  • antipsychotics (drugs to stabilize thinking and behavior)
  • anti-asthmatic (salmeterol)

PROPER USE OF THIS MEDICATION

Take MYLAN-TOLTERODINE ER as instructed by your doctor. Do not increase, decrease or stop taking MYLAN-TOLTERODINE ER without first talking to your doctor.

Usual dose:

The usual starting dose is 4 mg once daily, but may be decreased to 2 mg once daily. The capsule should be swallowed whole. MYLAN-TOLTERODINE ER can be taken with food.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Do not take more capsules than your doctor has told you to. If you take too many tablets by accident, call your doctor or pharmacist or a poison control centre immediately.

Missed Dose:

If you miss taking your capsule, take it as soon as you remember. But if it is almost time for the next dose, skip the missed dose and just take the next dose. Do not take more than one dose at a time.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

As with most drugs, MYLAN-TOLTERODINE ER can cause some side effects.

Tell your doctor or pharmacist right away if you suffer from any of the following side effects while taking this medication:

  • dry mouth
  • s t o m a c h p a i n
  • decreased tear production (dry irritable eye)
  • h e a r t b u r n
  • b l u r r e d v i s i o n
  • dizziness

    • palpitations (sensation of rapid, pounding, or irregular heart beat)
    • f a i n t i n g
    • difficulty in urination (passing water)

The most common side effect is dry mouth. Less commonly reported side effects are headache, constipation, dizziness, fatigue, abdominal pain and dry eyes.

If you experience any symptoms of a possible heart rhythm disturbance, such as dizziness, palpitations (sensation of rapid, pounding, or irregular heart beat), fainting, or seizures, you should stop taking MYLAN-TOLTERODINE ER and seek mediate medical attention.

Check with your doctor or pharmacist right away if you have any bothersome or unusual effects while taking MYLAN-TOLTERODINE ER.

Use caution while driving or using machinery until you know how MYLAN-TOLTERODINE ER affects you.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY

HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effectTalk with your doctor or pharmacistStop taking drug and seek immediate emergency medical attention

Only if

severe

In all cases
Uncommon

Allergic

reaction

√

This is not a complete list of side effects. For any unexpected effects while taking MYLAN-TOLTERODINE ER, stop taking the drug and contact your doctor or pharmacist.

Store at room temperature 15ºC to 30ºC. Protect from light.

You should not use your medication after the expiration date printed on the carton and label.

Keep all medications out of the reach of children. This medication could harm them.

PROPER USE OF THIS MEDICATION

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

IMPORTANT: PLEASE READ

REPORTING SUSPECTED SIDE EFFECTS

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

  • Online at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
  • By calling 1-866-234-2345 (toll-free);
  • By completing a Consumer Side Effect Reporting Form and sending it by:

    • Fax to 1-866-678-6789 (toll-free), or
    • Mail to: Canada Vigilance Program

      Health Canada, Postal Locator 0701E Ottawa, ON

      K1A 0K9

      Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect. (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php)

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

For more information, please contact your healthcare professionals or pharmacist first, or Mylan Pharmaceuticals ULC Canada at:1-800-668-3174, or visit the website at www.mylan.ca

Last prepared: April 28, 2015

MORE INFORMATION

IMPORTANT: PLEASE READ

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02404184

Revision date stated in the text: April 28, 2015

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Mylan-Tolterodine ER

Rx or OTC
Prescription (Rx)?
DIN 02404184, 02404192
Schedule(s) PRESCRIPTION
Active ingredient(s) Tolterodine tartrate
Dosage form(s) Capsule (Extended-Release)
Route(s) of administration Oral
Drug class (WHO ATC)
  1. G Genito urinary system and sex hormones
    1. G04 Urologicals
      1. G04B Urologicals
        1. G04BD Drugs for urinary frequency and incontinence
          1. G04BD07 Tolterodine
Company MYLAN PHARMACEUTICALS ULC
Current status Cancelled Post Market
Current status date February 14, 2022
Strengths and forms
DIN Strength Dosage form(s) Current status
02404184 2 MG Capsule (Extended-Release) Cancelled Post Market February 14, 2022
02404192 4 MG Capsule (Extended-Release) Cancelled Post Market February 14, 2022

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.